Healthcare Industry News: Immunovia
News Release - December 6, 2019
Biovica Strengthens Management Team
STOCKHOLM, Dec. 6, 2019 -- (Healthcare Sales & Marketing Network) -- Biovica, active in cancer diagnostics, today announced that Henrik Winther was appointed SVP Business Development and will be part of the management team. He most recently comes from the role of SVP Precision Diagnostics at Immunovia.Winther has previously worked as Global VP of Business Development at the Danish diagnostics company Dako and later as General Manager of the Companion Diagnostic (CDx) Division at Agilent Technologies based in California. Earlier in his career, Winther headed the R&D diagnostic reagents development at Dako. Prior to that he was associate professor in anatomy, physiology and cell biology at the University of Copenhagen. He will start at Biovica on November 18.
"For a decade, Companion Diagnostics i.e. patient stratification for the right individualized treatment has been the focus of the industry. Now, the next very important topic to secure safe and effective treatments within personalized cancer medicine is the monitoring of patient response to therapy," said Winther.
"Biovica is in a strong position with its DiviTum test which provides a unique tool to oncologists that allows for a fast, robust and reliable assessment of patients' response to a given treatment. DiviTum really has a great potential as it is already CE marked, has interesting applications, support from key opinion leaders globally and several excellent clinical study results. The pieces are in place to take Biovica to the next level," he said.
Source: Biovica International
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
